Sublingual immunotherapy provides an early increase of interferon-gamma production

J Biol Regul Homeost Agents. 2008 Jul-Sep;22(3):169-73.

Abstract

Allergic rhinitis (AR) is characterized by Th2 polarized immune response. Allergen-specific subcutaneous immunotherapy may restore a physiologic Th1 profile. However, there are few studies investigating the immunological effects of sublingual immunotherapy (SLIT). The aim of this study is to investigate whether a pre-seasonal SLIT course could affect IFN-gamma production. Forty-four AR patients with pollen allergy assumed pre-seasonal SLIT for 3 months. IFN-gamma-specific producing cells were assessed by cytokine ELISPOT before and 3 months after the beginning of SLIT. Visual analogue scale (VAS) for symptoms and medication score was also evaluated. The frequency of IFN-gamma-specific producing cells significantly increased after SLIT (p<0.01), and this increase was significantly associated with improvement of both symptoms (p<0.001) and medication use (p<0.01). In conclusion, these results may be considered clinically relevant as SLIT treatment may induce a quick IFN- gamma response that is related to clinical improvement.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Sublingual
  • Adolescent
  • Adult
  • Aged
  • Female
  • Humans
  • Immunotherapy*
  • Interferon-gamma / biosynthesis*
  • Male
  • Middle Aged
  • Rhinitis, Allergic, Perennial / immunology
  • Rhinitis, Allergic, Perennial / metabolism
  • Rhinitis, Allergic, Perennial / prevention & control
  • Rhinitis, Allergic, Perennial / therapy
  • Time Factors
  • Treatment Outcome

Substances

  • Interferon-gamma